Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Benzothiazinone compound and its preparation method and pharmaceutical use

A benzothiazinone and compound technology, applied in the field of medicinal chemistry, can solve the problems of selectivity and specificity that cannot be ignored, and the effect of ovarian cancer is small.

Active Publication Date: 2021-09-07
FUDAN UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In 2006, LiCl was reported to have a better anti-proliferation effect on ovarian cancer cells in vivo, but LiCl at physiological levels had little effect on ovarian cancer (Cao Q, et al., Cell Res. 16(2006) 671-677, Novetsky AP, et al., Int J Gynecol Cancer 23 (2013) 361-366)
[0006] Most of the GSK-3β inhibitors currently reported are ATP competitive inhibitors. Since the ATP binding region is highly conserved among more than 500 kinases, the selectivity and specificity problems caused by acting on this active region cannot be ignored.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzothiazinone compound and its preparation method and pharmaceutical use
  • Benzothiazinone compound and its preparation method and pharmaceutical use
  • Benzothiazinone compound and its preparation method and pharmaceutical use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Preparation of 4-ethyl-N-(1-nonanoylpiperidin-4-yl)-3-oxo-3,4-dihydro-(2H)benzo[1,4]thiazine-2-carboxamide ( 17a)

[0031] Preparation of 4-ethyl-(2H)1,4-benzothiazin-3(4H)-one (3)

[0032]

[0033] Into a 100 mL round bottom flask was added (2H)1,4-benzothiazin-3(4H)-one (2.5 g, 0.015 mol), sodium hydroxide powder (0.7 g, 0.016 mol), N,N-di Methylformamide (50mL) and ethyl bromide (1.5mL, 0.019mol) were reacted at room temperature, and the reaction was terminated by the disappearance of the raw material point as detected by TLC. Extracted with dichloromethane, combined organic layers, washed successively with 1N aqueous hydrochloric acid solution, saturated aqueous sodium bicarbonate solution, and saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove solvent, and obtained 3.3 g of light yellow oil, which was directly used in Next reaction. Preparation of 2-methoxyformyl-4-ethyl-(2H)1,4-benzothiazin-3(4H)-one (5)

[0...

Embodiment 2

[0049] Preparation of N-(1-decanoylpiperidin-4-yl)-4-ethyl-3-oxo-3,4-dihydro-(2H)benzo[1,4]thiazine-2-carboxamide ( 17b)

[0050]

[0051] The preparation method was the same as that of 17a, except capric acid was used instead of nonanoic acid, the reaction solvent was N,N-dimethylformamide (DMF), the reaction temperature was 25°C, and the catalyst was TBTU / DIPEA to obtain a white flaky solid with a yield of 46%. 1 H NMR (400MHz, DMSO-d6) δ8.12 (d, J = 7.6Hz, 1H), 7.39 (d, J = 7.6Hz, 1H), 7.30-7.29 (m, 2H), 7.05-7.04 (m, 1H),4.25(s,1H),4.16-3.90(m,3H),3.76-3.65(m,2H),3.10-3.00(m,1H),2.75-2.67(m,1H),2.26-2.25( m, 2H), 1.76-1.24 (m, 18H), 1.14 (t, J=6.8Hz, 3H), 0.85 (t, J=6.6Hz, 3H).

Embodiment 3

[0053] Preparation of 4-ethyl-3-oxo-N-(1-undecanoylpiperidin-4-yl)-3,4-dihydro-(2H)benzo[1,4]thiazine-2-carboxamide (17c)

[0054]

[0055] The preparation method is the same as 17a, using undecanoic acid instead of pelargonic acid, white flaky solid, yield 63%. 1 H NMR (400MHz, DMSO-d6) δ8.12 (d, J = 7.2Hz, 1H), 7.39 (d, J = 7.2Hz, 1H), 7.30-7.29 (m, 2H), 7.06-7.04 (m, 1H),4.25(s,1H),4.16-3.90(m,3H),3.76-3.65(m,2H),3.09-3.00(m,1H),2.75-2.67(m,1H),2.26-2.25( m, 2H), 1.76-1.24 (m, 20H), 1.14 (t, J = 7.0Hz, 3H), 0.85 (t, J = 6.4Hz, 3H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicinal chemistry, and relates to a benzothiazinone compound of the general structure formula I, a preparation method thereof and a medicinal application thereof. The benzothiazinone compound shown in the general structural formula of formula I of the present invention is a non-ATP competitive small molecule inhibitor of GSK-3β, which can selectively inhibit the activity of glycogen synthesis kinase-3β (GSK-3β), It can be used to prepare medicines for preventing or treating diseases related to GSK‑3β. The compound of formula I described in the present invention has better inhibitory activity on tumors in vivo and in vitro, and can be used to prepare drugs for preventing or treating tumors. The present invention also includes a method for synthesizing the benzothiazinone compound of formula I.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and relates to a novel benzothiazinone compound with the structure of formula I, a preparation method and a medicinal application thereof. The benzothiazinone compound of the formula I structure described in the present invention is an allosteric regulation inhibitor of glycogen synthesis kinase-3β (GSK-3β), which can inhibit the activity of GSK-3β at micromolar concentration, and is effective for various tested There was no significant inhibitory effect on protein kinases. The compound can be used for preparing medicine for treating ovarian cancer tumor or preparing medicine for preventing or treating diseases related to GSK-3β. Background technique [0002] The prior art discloses that glycogen synthase kinase-3β (Glycogen synthase kinase-3β, GSK-3β) is a highly conserved multifunctional serine / threonine protein kinase, because it can phosphorylate glycogen synthase and make It got its name...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D279/16C07D417/12A61K31/5415A61P35/00A61P3/10A61P25/28
CPCC07D279/16C07D417/12
Inventor 楚勇高扬叶德泳
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com